Curis’s Strategic Clinical Advancements and Promising Data Drive Buy Rating
Curis has received a Buy rating from analyst Soumit Roy of JonesTrading, with a price target of $5.00. This rating is based on Curis's upcoming clinical data updates and strategic focus on key trials, particularly in PCNSL and CLL. Promising results from a Phase 1 study of emavusertib in AML patients further support this positive outlook. Significant clinical data is expected at major medical conferences, enhancing Curis's prospects in the healthcare sector.
Curis, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading reiterated a Buy rating on the stock and has a $5.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Soumit Roy has given his Buy rating due to a combination of factors related to Curis’s upcoming clinical data updates and their strategic focus on key trials. Curis is poised to release significant clinical data at major medical conferences such as SNO, ASH, and ASCO-GI, which could potentially enhance the company’s prospects. The focus on Phase 2 trials in PCNSL and CLL over the next year indicates a strategic direction aimed at advancing their pipeline.
Furthermore, Curis’s recent data from a Phase 1 study involving emavusertib in combination with other treatments showed promising results, including a notable MRD conversion rate in AML patients. The company’s efforts to enroll patients in their Phase 2 study and the anticipated updates from ongoing trials suggest a proactive approach to clinical development. These factors collectively contribute to the positive outlook and Buy rating assigned by Soumit Roy.
